Scarica l'app Stockscreener
26.73
4.77%
-1.34
Dopo l'orario di chiusura:
26.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HROW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$28.07
Aprire:
$27.66
Volume 24 ore:
300.21K
Relative Volume:
0.58
Capitalizzazione di mercato:
$980.99M
Reddito:
$154.15M
Utile/perdita netta:
$-33.58M
Rapporto P/E:
-27.84
EPS:
-0.96
Flusso di cassa netto:
$-20.74M
1 W Prestazione:
+6.39%
1M Prestazione:
+15.02%
6M Prestazione:
-39.08%
1 anno Prestazione:
+62.10%
Intervallo 1D:
$26.55
$28.10
Intervallo di 1 settimana:
$24.62
$28.48
Portata 52W:
$15.97
$59.23
Harrow Inc Stock (HROW) Company Profile
Nome
Harrow Inc
Settore
Telefono
615.733.4731
Indirizzo
1A BURTON HILLS BLVD, NASHVILLE, CA
Confronta HROW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
26.73 | 964.10M | 154.15M | -33.58M | -20.74M | -0.96 |
|
HLN
Haleon Plc Adr
|
11.10 | 47.07B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
161.44 | 71.42B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.90 | 3.34M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.32 | 42.86B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.55 | 20.05B | 16.54B | -1.64B | 749.00M | -1.45 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-04 | Reiterato | B. Riley Securities | Buy |
| 2024-04-11 | Iniziato | Craig Hallum | Buy |
| 2022-09-08 | Ripresa | B. Riley Securities | Buy |
| 2021-10-14 | Ripresa | B. Riley Securities | Buy |
| 2021-09-24 | Iniziato | Aegis Capital | Buy |
| 2021-07-02 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Harrow Inc Borsa (HROW) Ultime notizie
Harrow Inc.: Opaleye management sells $150,055 in stock By Investing.com - Investing.com India
Harrow Inc.: Opaleye management sells $150,055 in stock - Investing.com
Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Insider Monkey
Harrow to Present at Two Investor Conferences in May - Business Wire
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock - Benzinga
Harrow Health, Inc. (NASDAQ:HROW) Q1 2025 Earnings Call Transcript - Insider Monkey
Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO - GuruFocus
HROW Stock Price Target Raised to $60 by Analyst | HROW Stock Ne - GuruFocus
Where Harrow Stands With Analysts - Benzinga
HROW Stock Update: Analyst Raises Price Target to $60 | HROW Sto - GuruFocus
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates - MSN
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Reven - GuruFocus
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... By GuruFocus - Investing.com Canada
Harrow Health Reports Strong Q1 2025 Revenue Growth - TipRanks
Harrow Announces First-Quarter 2025 Financial Results - BioSpace
Transcript : Harrow, Inc., Q1 2025 Earnings Call, May 09, 2025 - marketscreener.com
Harrow Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Harrow: Q1 Earnings Snapshot - CT Insider
Harrow Health Q1 2025 slides: revenue up 43% as ophthalmic portfolio expands - Investing.com
Harrow Health (HROW) Reports Q1 Revenue Miss Despite Growth - GuruFocus
Harrow Inc (HROW) Q1 2025 Earnings: EPS of -$0.50 Misses Estimate, Revenue at $47.8M Below Forecast - GuruFocus
Earnings Flash (HROW) HARROW INC. Reports Q1 Loss $0.38 Per Share - marketscreener.com
Harrow (HROW) Sees Promising Revenue Growth and Expansion Plans - GuruFocus
HROW Forecasts Surpassing $280 Million Revenue by 2025 | HROW St - GuruFocus
HROW Forecasts Surpassing $280 Million Revenue by 2025 | HROW Stock News - GuruFocus
Harrow (HROW) Sees Promising Revenue Growth and Expansion Plans | HROW Stock News - GuruFocus
Harrow Inc (HROW) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Harrow to Report First Quarter 2025 Financial Results After Mark - GuruFocus
Examining the Future: Harrow's Earnings Outlook - Nasdaq
What To Expect From Harrow Inc (HROW) Q1 2025 Earnings - Yahoo Finance
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 - Business Wire
Invesco Ltd. Lowers Position in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow, Inc. (NASDAQ:HROW) Shares Sold by Wells Fargo & Company MN - Defense World
Harrow Inc (HROW) Shares Gap Down to $24.695 on Apr 28 - GuruFocus
Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - MSN
JPMorgan Chase & Co. Lowers Stock Position in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic L - GuruFocus
Harrow Authorizes Nordic Group Unit to sell Generic Version of Maxitrol eye Treatment - marketscreener.com
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - Morningstar
LPL Financial LLC Has $699,000 Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives Propel Success - GuruFocus
Harrow Inc (NASDAQ: HROW) Jumps 2.74%: The Most Likely Path Going Forward - Stocksregister
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Business Wire
Harrow Inc Azioni (HROW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.50%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):